Investor Overview

Press Release

<< Back
02/26/18
Orthofix International Reports Fourth Quarter and Fiscal 2017 Financial Results

 

Fourth Quarter Highlights

  • Net sales of $116.9 million, an increase of 7.7% compared to prior year and 6.1% on a constant currency basis
  • Net income from continuing operations of $1.5 million; compared to net loss of $5.1 million in the prior year
  • Adjusted EBITDA of $24.3 million; an increase of $3.2 million, or 15.1%, over prior year

Fiscal Year 2017 Highlights

  • Net sales of $433.8 million, an increase of 5.9% compared to prior year and 5.5% on a constant currency basis
  • Net income from continuing operations of $7.3 million; an increase of $3.8 million over prior year
  • Adjusted EBITDA of $81.6 million; an increase of $2.3 million, or 2.9%, over prior year

LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2017. For the fourth quarter of 2017, net sales were $116.9 million, earnings per share from continuing operations was $0.08 and adjusted earnings per share from continuing operations was $0.52. For fiscal year 2017, net sales were $433.8 million, earnings per share from continuing operations was $0.39 and adjusted earnings per share from continuing operations was $1.62.

"2017 was a very strong year for Orthofix. We exceeded our topline expectations and finished the year with a solid margin improvement trajectory. We also made significant progress in the transformation of our Spine Fixation business and completed our worldwide restructuring initiatives," said Brad Mason, President and Chief Executive Officer.

"With 2017 in the rear-view mirror, we are now focused fully on executing our 2018 global and business unit strategies. Globally, we expect to drive shareholder value through three pillars, topline organic growth better than market growth rates, margin expansion through operational improvements, and strategic deployment of our capital in ways that we believe will accelerate topline growth in our core businesses. We are well positioned and expect to execute in each of these areas in 2018."

Financial Results Overview

Fourth Quarter

The following table provides net sales by strategic business unit ("SBU"):

       
      Three Months Ended December 31,
(Unaudited, U.S. Dollars, in thousands)     2017     2016     Change    

Constant
Currency
Change

BioStim     $ 49,760     $ 47,803     4.1 %     4.1 %
Extremity Fixation       29,103       26,843     8.4 %     2.2 %
Spine Fixation       21,175       18,664     13.5 %     13.2 %
Biologics       16,858       15,227     10.7 %     10.7 %
Net sales     $ 116,896     $ 108,537     7.7 %     6.1 %
                                 

Gross profit increased $8.1 million to $93.3 million. Gross margin increased to 79.8% compared to 78.5% in the prior year period, primarily due to increased revenue from international Extremity Fixation stocking distributors, as well as our domestic and international restructuring initiatives during 2017. Non-GAAP net margin (gross profit less sales and marketing expenses) was $41.5 million, an increase of 13.6% compared to $36.5 million in the prior year period. The increase in non-GAAP net margin was primarily due to the increase in gross margin and a slight decrease in sales and marketing expenses as a percent of sales.

Net income from continuing operations was $1.5 million, or $0.08 per share, compared to net loss of $5.1 million, or ($0.29) per share in the prior year period. Adjusted net income from continuing operations was $9.7 million, or $0.52 per share, compared to adjusted net income of $7.7 million, or $0.42 per share in the prior year period.

EBITDA was $21.8 million, compared to $8.6 million in the prior year period. Adjusted EBITDA was $24.3 million or 20.8% of net sales for the fourth quarter, compared to $21.1 million or 19.4% of net sales in the prior year period.

Fiscal Year 2017

The following table provides net sales by SBU:

       
      Year Ended December 31,
(U.S. Dollars, in thousands)     2017     2016     Change    

Constant
Currency
Change

BioStim     $ 185,900     $ 176,561     5.3 %     5.3 %
Extremity Fixation       103,242       102,683     0.5 %     (0.9 %)
Spine Fixation       81,957       72,632     12.8 %     12.7 %
Biologics       62,724       57,912     8.3 %     8.3 %
Net sales     $ 433,823     $ 409,788     5.9 %     5.5 %
                                 

Driven by the increase in net sales, gross profit increased $18.9 million to $340.8 million, while gross margin was flat at 78.6% compared to the prior year period. Non-GAAP net margin was $142.4 million, an increase of 1.3% compared to $140.6 million in the prior year period. The increase in Non-GAAP net margin was due to the increase in net sales, partially offset by higher commission expenses from geographic mix in Extremity Fixation and higher commission rates from Biologics and Spine Fixation distributors.

Net income from continuing operations was $7.3 million, or $0.39 per share, compared to net income of $3.5 million, or $0.19 per share in the prior year. Adjusted net income from continuing operations was $30.1 million, or $1.62 per share, compared to adjusted net income of $27.0 million, or $1.46 per share in the prior year.

EBITDA was $56.9 million in 2017, compared to $39.1 million in the prior year. Adjusted EBITDA was $81.6 million or 18.8% of net sales for the year, compared to $79.3 million or 19.4% of net sales in the prior year.

Adoption of Revenue Recognition Standard ASU 2014-09

On January 1, 2018, the Company adopted the new revenue recognition standard, ASU 2014-09, as amended, using a cumulative effect adjustment, which resulted in a significant increase in accounts receivable, a decrease in inventories, and a related change to deferred income taxes. These changes were offset by an adjustment to the Company's opening retained earnings of approximately $5 million. One of the primary impacts of this new standard is the timing of revenue recognition for our sales to international Extremity Fixation and Spine Fixation stocking distributors that were historically accounted for using the sell-through method. This revenue will now be recorded on invoiced sales instead of deferring recognition until cash is received. If the Company were to have adopted the new standard as of January 1, 2017, pro-forma net sales for the year ended December 31, 2017 would have been approximately $431 million. Refer to the table under the subheading "2017 Pro-forma Net Sales Under the New Revenue Recognition Standard" for the detail of pro-forma 2017 net sales by quarter as would have been reported under the new revenue recognition standard.

Liquidity

As of December 31, 2017, cash and cash equivalents were $81.2 million compared to $39.6 million as of December 31, 2016. As of December 31, 2017, we had no outstanding indebtedness and borrowing capacity of $125 million. Cash flow from operations increased $8.6 million to $53.3 million, while free cash flow increased $10.0 million to $36.4 million.

Redomicile

The Company is in the final stages of evaluating the impact of moving its parent company's domicile from Curacao to the United States. Based on the analysis to date, including the assessment of the recent U.S. tax reform, the Company believes that executing this change could provide a number of benefits to Orthofix, including organizational simplification, more efficient cash deployment, a lower tax rate and increased cash flow. Subject to the outcome of final diligence, the Company currently anticipates requesting shareholder approval for this move in conjunction with its annual shareholder meeting later this year. The Company also expects to incur costs this year to complete all of the underlying steps required for this transition. These estimated costs are included in our 2018 guidance.

2018 Outlook

For the year ending December 31, 2018, the Company expects the following results, assuming exchange rates are the same as those currently prevailing. This guidance reflects the new revenue recognition standard that is required as of January 1, 2018 and discussed above, for which net sales will be recorded on invoiced sales instead of deferring recognition until cash is received.

           
      2018 Outlook    
(Unaudited, U.S. Dollars, in millions, except per share data)     Low         High    
Net sales     $ 450.0   1     $ 455.0   1
Net income from continuing operations     $ 28.3   2     $ 30.6   2
Adjusted EBITDA     $ 89.0   3     $ 91.0   3
EPS from continuing operations     $ 1.50   4     $ 1.62   4
Adjusted EPS from continuing operations     $ 1.76   5     $ 1.84   5
                         
1   Represents a year-over-year increase of 3.7% to 4.9% on a reported basis
2   Represents a year-over-year increase of 288.1% to 319.7%
3   Represents a year-over-year decrease of 9.1% to 11.6%
4   Represents a year-over-year increase of 284.6% to 315.4%
5   Represents a year-over-year increase of 8.6% to 13.6%
     

Conference Call

Orthofix will host a conference call today at 4:30 PM Eastern time to discuss the Company's financial results for the fourth quarter and fiscal year 2017. Interested parties may access the conference call by dialing (844) 809-1992 in the U.S. and (612) 979-9886 outside the U.S., and referencing the conference ID 7995595. A replay of the call will be available for two weeks by dialing (855) 859-2056 in the U.S. and (404) 537-3406 outside the U.S., and entering the conference ID 7995595. A webcast of the conference call may be accessed by going to the Company's website at www.orthofix.com, by clicking on the Investors link and then the Events and Presentations page.

About Orthofix

Orthofix International N.V. is a global medical device company focused on musculoskeletal healing products and value-added services. The Company's mission is to improve patients' lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, the Company has four strategic business units: BioStim, Extremity Fixation, Spine Fixation, and Biologics. Orthofix products are widely distributed via the Company's sales representatives and distributors. For more information, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended ("the Exchange Act"), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," or "continue" or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to further update any such statement, or the risk factors described in Part I, Item 1A under the heading Risk Factors in our Form 10-K for the year ended December 31, 2017, to reflect new information, the occurrence of future events or circumstances or otherwise.

               
               
ORTHOFIX INTERNATIONAL N.V.
Consolidated Statements of Operations
               
               
      Three Months Ended       Year Ended
      December 31,       December 31,
(U.S. Dollars, in thousands, except share and per share data)     2017     2016       2017     2016
      (unaudited)              
Net sales     $ 116,896       $ 108,537         $ 433,823       $ 409,788  
Cost of sales       23,562         23,320           93,037         87,853  
Gross profit       93,334         85,217           340,786         321,935  
Sales and marketing       51,874         48,705           198,370         181,287  
General and administrative       19,480         21,063           74,388         74,404  
Research and development       8,454         7,509           29,700         28,803  
SEC / FCPA matters and related costs       (4,334 )       524           (2,483 )       2,005  
Charges related to U.S. Government resolutions                                 14,369  
Operating income       17,860         7,416           40,811         21,067  
Interest income (expense), net       (522 )       443           (416 )       763  
Other expense, net       (720 )       (4,152 )         (4,004 )       (2,806 )
Income before income taxes       16,618         3,707           36,391         19,024  
Income tax expense       (15,102 )       (8,824 )         (29,100 )       (15,527 )
Net income (loss) from continuing operations       1,516         (5,117 )         7,291         3,497  
Discontinued operations                          
Income (loss) from discontinued operations       3         2,942           (1,759 )       (638 )
Income tax (expense) benefit       49         (1,061 )         691         197  
Net income (loss) from discontinued operations       52         1,881           (1,068 )       (441 )
Net income (loss)     $ 1,568       $ (3,236 )       $ 6,223       $ 3,056  
Net income (loss) per common share—basic                          
Net income (loss) from continuing operations     $ 0.08       $ (0.29 )       $ 0.40       $ 0.19  
Net income (loss) from discontinued operations       0.01         0.11           (0.06 )       (0.02 )
Net income (loss) per common share—basic     $ 0.09       $ (0.18 )       $ 0.34       $ 0.17  
Net income (loss) per common share—diluted                          
Net income (loss) from continuing operations     $ 0.08       $ (0.29 )       $ 0.39       $ 0.19  
Net income (loss) from discontinued operations       -         0.11           (0.05 )       (0.02 )
Net income (loss) per common share—diluted     $ 0.08       $ (0.18 )       $ 0.34       $ 0.17  
Weighted average number of common shares:                          
Basic       18,254,831         17,862,531           18,117,405         18,144,019  
Diluted       18,773,786         17,862,531           18,498,745         18,463,161  
                                           
           
ORTHOFIX INTERNATIONAL N.V.
Consolidated Balance Sheets
           
           
(U.S. Dollars, in thousands except share data)  

December 31,
2017

   

December 31,
2016

Assets          
Current assets          
Cash and cash equivalents   $ 81,157     $ 39,572  
Restricted cash     -       14,369  

Trade accounts receivable, less allowance for doubtful accounts of $8,405 and $8,396 at December 31, 2017 and 2016, respectively

    63,437       57,848  
Inventories     81,330       63,346  
Prepaid expenses and other current assets     25,877       19,238  
Total current assets     251,801       194,373  
Property, plant and equipment, net     45,139       48,916  
Patents and other intangible assets, net     10,461       7,461  
Goodwill     53,565       53,565  
Deferred income taxes     23,315       47,325  
Other long-term assets     21,073       20,463  
Total assets   $ 405,354     $ 372,103  
Liabilities and shareholders' equity          
Current liabilities          
Trade accounts payable   $ 18,111     $ 14,353  
Other current liabilities     61,295       69,088  
Total current liabilities     79,406       83,441  
Other long-term liabilities     29,340       25,185  
Total liabilities     108,746       108,626  
Contingencies          
Shareholders' equity          

Common shares $0.10 par value; 50,000,000 shares authorized; 18,278,833 and 17,828,155 issued and outstanding as of December 31, 2017 and 2016, respectively

    1,828       1,783  
Additional paid-in capital     220,591       204,095  
Retained earnings     70,402       64,179  
Accumulated other comprehensive income (loss)     3,787       (6,580 )
Total shareholders' equity     296,608       263,477  
Total liabilities and shareholders' equity   $ 405,354     $ 372,103  
                 
                 

ORTHOFIX INTERNATIONAL N.V.
Non-GAAP Financial Measures

The following tables present reconciliations of net income (loss) from continuing operations, earnings per share from continuing operations, gross profit, and net cash from operating activities, in each case calculated in accordance with U.S. generally accepted accounting principles ("GAAP"), to, as applicable, non-GAAP financial measures, referred to as "EBITDA," "Adjusted EBITDA," "Adjusted net income from continuing operations," "Adjusted earnings per share from continuing operations," "Non-GAAP net margin" and "Free cash flow" that exclude items specified in the tables. A more detailed explanation of the items excluded from these non-GAAP financial measures, as well as why management believes the non-GAAP financial measures are useful to them, is included following the reconciliations.

EBITDA and Adjusted EBITDA

               
     

Three Months Ended
December 31,

     

Year Ended
December 31,

(Unaudited, U.S. Dollars, in thousands)     2017     2016       2017     2016
Net income (loss) from continuing operations     $ 1,516       $ (5,117 )       $ 7,291       $ 3,497  
Interest expense (income), net       522         (443 )         416         (763 )
Income tax expense       15,102         8,824           29,100         15,527  
Depreciation and amortization       4,703         5,358           20,124         20,841  
EBITDA     $ 21,843       $ 8,622         $ 56,931       $ 39,102  
Share-based compensation       3,433         3,812           12,557         15,686  
Foreign exchange impact       491         1,475           (1,934 )       41  
Strategic investments       1,993         2,726           11,612         3,068  
SEC / FCPA matters and related costs       (4,334 )       524           (2,483 )       2,005  
Infrastructure investments               478                   3,551  
Legal judgments/settlements       79         1,446           1,877         (1,554 )
Charges related to U.S. Government resolutions                                 14,369  
Restructuring       764         1,964           3,006         1,964  
Succession charges               40                   1,066  
Adjusted EBITDA     $ 24,269       $ 21,087         $ 81,566       $ 79,298  
As a % of net sales       20.8 %       19.4 %         18.8 %       19.4 %
                                           
                                           

Adjusted Net Income from Continuing Operations

           
     

Three Months Ended
December 31,

 

Year Ended
December 31,

(Unaudited, U.S. Dollars, in thousands)     2017   2016   2017   2016
Net income (loss) from continuing operations     $ 1,516     $ (5,117 )   $ 7,291     $ 3,497  
Foreign exchange impact       491       1,475       (1,934 )     41  
Strategic investments       1,993       2,726       11,612       3,068  
SEC / FCPA matters and related costs       (4,334 )     524       (2,483 )     2,005  
Infrastructure investments             478             3,551  
Legal judgments/settlements       79       1,446       1,877       (1,554 )
Charges related to U.S. Government resolutions                         14,369  
Restructuring       764       1,964       3,006       1,964  
Succession charges             40             1,066  
Long-term income tax rate adjustment       9,170       4,127       10,682       (1,016 )
Adjusted net income from continuing operations     $ 9,679     $ 7,663     $ 30,051     $ 26,991  
                                   
                                   

Adjusted Earnings per Share from Continuing Operations

               
     

Three Months Ended
December 31,

     

Year Ended
December 31,

(Unaudited, per diluted share)     2017     2016       2017     2016
EPS from continuing operations     $ 0.08       $ (0.29 )       $ 0.39       $ 0.19  
Foreign exchange impact       0.03         0.08           (0.10 )        
Strategic investments       0.11         0.15           0.63         0.16  
SEC / FCPA matters and related costs       (0.23 )       0.03           (0.13 )       0.11  
Infrastructure investments               0.03                   0.19  
Legal judgments/settlements               0.08           0.09         (0.08 )
Charges related to U.S. Government resolutions                                 0.78  
Restructuring       0.04         0.11           0.16         0.11  
Succession charges                                 0.06  
Long-term income tax rate adjustment       0.49         0.23           0.58         (0.06 )
Adjusted EPS from continuing operations     $ 0.52       $ 0.42         $ 1.62       $ 1.46  
                           
Weighted average number of diluted common shares       18,773,786         18,148,655           18,498,745         18,463,161  
                                           
                                           

Non-GAAP Net Margin

               
     

Three Months Ended
December 31,

     

Year Ended
December 31,

(Unaudited, U.S. Dollars, in thousands)     2017     2016       2017     2016
Gross profit     $ 93,334       $ 85,217         $ 340,786       $ 321,935  
Sales and marketing       (51,874 )       (48,705 )         (198,370 )       (181,287 )
Non-GAAP net margin     $ 41,460       $ 36,512         $ 142,416       $ 140,648  
                           
BioStim     $ 22,482       $ 20,489         $ 77,369       $ 75,469  
Extremity Fixation       10,170         6,356           31,071         30,526  
Spine Fixation       1,905         2,725           8,730         8,650  
Biologics       7,041         7,249           25,692         26,891  
Corporate       (138 )       (307 )         (446 )       (888 )
Non-GAAP net margin     $ 41,460       $ 36,512         $ 142,416       $ 140,648  
                                           
                                           

Free Cash Flow

       
     

Year Ended
December 31,

(Unaudited, U.S. Dollars, in thousands)     2017     2016
Net cash from operating activities     $ 53,341       $ 44,707  
Capital expenditures       (16,948 )       (18,334 )
Free cash flow     $ 36,393       $ 26,373  
                     
                     

2017 Pro-forma Net Sales Under the New Revenue Recognition Standard

       
      Year Ended December 31, 2017
(Unaudited, U.S. Dollars, in millions)     1st Quarter     2nd Quarter     3rd Quarter     4th Quarter     Year
Net sales (as would be reported under ASU 2014-09)     $ 105     $ 109     $ 104       $ 113       $ 431  
Net sales (as reported)       103       109       105         117         434  
Variance     $ 2     $ -     $ (1 )     $ (4 )     $ (3 )
                                               
                                               

2018 Outlook

       
      2018 Outlook
(Unaudited, U.S. Dollars, in millions)     Low     High
Net income from continuing operations     $ 28.3       $ 30.6  
Interest expense, net       (0.3 )       (0.3 )
Income tax expense       16.6         17.9  
Depreciation and amortization       19.8         19.8  
EBITDA     $ 64.4       $ 68.0  
Share-based compensation       18.2         18.1  
Strategic investments       7.0         6.0  
SEC / FCPA matters and related costs       1.0         0.5  
Foreign exchange impact       (1.8 )       (1.8 )

Legal judgments/settlements

      0.2         0.2  
Adjusted EBITDA     $ 89.0       $ 91.0  
       
       
      2018 Outlook
(Unaudited, per diluted share)     Low     High
EPS from continuing operations     $ 1.50       $ 1.62  
Strategic investments       0.37         0.32  
SEC / FCPA matters and related costs       0.05         0.03  
Foreign exchange impact       (0.10 )       (0.10 )

Legal judgments/settlements

      0.01         0.01  
Long-term income tax rate adjustment       (0.07 )       (0.04 )
Adjusted EPS from continuing operations     $ 1.76       $ 1.84  
             
Weighted average number of diluted common shares       18,900,000         18,900,000  
                     
                     

Constant Currency

Constant currency is a non-GAAP measure, which is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

Pro-Forma Net Sales

Pro-forma net sales is a non-GAAP measure in fiscal 2017, which reflects what net sales in fiscal 2017 would have been, had the Company adopted ASU 2014-09, Revenue from Contracts with Customers, as amended, as of January 1, 2017, or elected to adopt the standard using the full retrospective transition method.

EBITDA

EBITDA is a non-GAAP financial measure, which is calculated by adding interest income (expense), net; income tax expense; and depreciation and amortization to net income (loss) from continuing operations. EBITDA provides management with additional insight to its results of operations.

Adjusted EBITDA, Adjusted Net Income from Continuing Operations and Adjusted Earnings per Share from Continuing Operations

These non-GAAP financial measures provide management with additional insight to its results of operations and are calculated using the following adjustments:

  • Share-based compensation - costs related to our share-based compensation plans, which include stock options, restricted stock awards, performance-based restricted stock awards, market-based restricted stock awards and our stock purchase plan; see the share-based compensation footnote in our Form 10-K for the year ended December 31, 2017 for a detail of these costs by income statement line item
  • Foreign exchange impact - gains and losses related to foreign currency transactions, which are recorded as other expense, net; guidance presented does not include the impact of any future foreign exchange fluctuations
  • Strategic investments - costs related to our strategic investments, including costs associated with evaluation of moving the domicile of the Company, which are recorded as general and administrative expenses, and recognized gains and losses on our investment in eNeura, Inc., which are recorded as other expense, net
  • SEC / FCPA matters and related costs - legal and other professional fees associated with the SEC Investigation, Securities Class Action Complaint and Brazil subsidiary compliance review
  • Infrastructure investments - costs associated with our multi-year process and systems improvement effort, "Bluecore," which was completed in 2016 and are recorded as general and administrative expenses
  • Legal judgments/settlements - adverse or favorable legal judgments or negotiated legal settlements, which are recorded as general and administrative expenses
  • Charges related to U.S. Government resolutions - charges related to the settlement with the SEC as further discussed in our Form 10-K for the year ended December 31, 2017
  • Restructuring - costs related to a planned restructuring, primarily consisting of severance charges and the write-down of certain assets, of which approximately 25% are recorded as cost of sales and 75% are recorded as other operating expenses
  • Succession charges - costs related to the succession of certain of our former named executive officers, which are recorded as general and administrative expenses
  • Long-term income tax rate adjustment - reflects management's expectation of a long-term normalized effective tax rate of 38% for 2017 results, and 35% going forward in 2018, which is based on current tax law and current expected income; actual reported tax expense will ultimately be based on GAAP earnings and may differ from the expected long-term normalized effective tax rate due to a variety of factors, including the resolutions of issues arising from tax audits with various tax authorities, the ability to realize deferred tax assets, the tax impact of strategic investments and other non-recurring events

Non-GAAP Net Margin

Non-GAAP net margin is an internal non-GAAP metric, which we define as gross profit less sales and marketing expense. Non-GAAP net margin is the primary metric used by our Chief Operating Decision Maker in managing our business.

Free Cash Flow

Free cash flow is a non-GAAP financial measure, which is calculated by subtracting capital expenditures from cash flow from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

Usefulness and Limitations of Non-GAAP Financial Measures

Management uses non-GAAP measures to evaluate performance period-over-period, to analyze the underlying trends in our business, to assess performance relative to competitors and to establish operational goals and forecasts that are used in allocating resources. Management uses these non-GAAP measures as the basis for assessing the ability of the underlying operations to generate cash. In addition, management uses these non-GAAP measures to further its understanding of the performance of our business units.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

The non-GAAP measures used in this press release may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost and can have a material effect on cash flows. Similarly, certain non-cash expenses, such as equity compensation, do not directly impact cash flows, but are part of total compensation costs accounted for under GAAP.

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

We compensate for the limitations of our non-GAAP financial measures by relying upon GAAP results to gain a complete picture of our performance. The GAAP results provide the ability to understand our performance based on a defined set of criteria. The non-GAAP measures reflect the underlying operating results of our businesses, which we believe is an important measure of our overall performance. We provide a detailed reconciliation of the non-GAAP financial measures to our most directly comparable GAAP measures, and encourage investors to review this reconciliation.

Usefulness of Non-GAAP Financial Measures to Investors

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. Management believes it is important to provide investors with the same non-GAAP metrics it uses to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to its historical operating results and internally evaluate the effectiveness of our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

 

Orthofix International N.V.
Mark Quick, 214-937-2924
markquick@orthofix.com

 

Source: Orthofix International N.V.

 

 

News Provided by Acquire Media